Flash Finance

JB Chemicals & Pharmaceuticals LimitedJBCHEPHARMCorporate

Healthcare Drug Manufacturers - Specialty & Generic Latest results: Mar 2026 14 quarters of data
Consolidated Standalone
₹2,408.90
MCap ₹38,677 Cr · P/E 54.5
JB Chemicals & Pharmaceuticals Limited — Stock analysis & AI research JB Chemicals & Pharmaceuticals Limited — Seasonality — best & worst months JB Chemicals & Pharmaceuticals Limited — Technical indicators & charts JB Chemicals & Pharmaceuticals Limited — Live exchange announcements
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹904 Cr
Sales · Mar 2026
-4.8% YoY
₹201 Cr
Operating Profit · Mar 2026
-11.2% YoY
22.2%
OPM % · Mar 2026
-6.7% YoY
₹101 Cr
Net Profit · Mar 2026
-30.7% YoY
₹6.31
EPS · Mar 2026
-32.6% YoY

📝 JB Chemicals & Pharmaceuticals Limited — results explained

Quarter ended March 2026 (Q4 FY26)

JB Chemicals & Pharmaceuticals Limited reported revenue of ₹904 crore for the quarter ended March 2026 (Q4 FY26), down 4.8% from ₹949 crore in the same quarter last year, and down 15.1% sequentially over the December 2025 quarter.

Net profit fell 30.7% year-on-year to ₹101 crore, from ₹146 crore. Earnings per share (EPS) came in at ₹6.31.

Operating profit stood at ₹201 crore — an operating margin (OPM) of 22.2%, compared with 23.8% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, JB Chemicals & Pharmaceuticals Limited posted revenue of ₹4,148 crore, a growth of 5.9% over FY25, with a net profit of ₹709 crore (up 7.5% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹4,148 crore with a net profit of ₹709 crore.

Valuation snapshot

At the current price of ₹2,408.90, JBCHEPHARM has a market capitalisation of ₹38,677 crore and a trailing P/E of about 54.5.

Within the Drug Manufacturers - Specialty & Generic industry, it is the 17th-largest of the 31 companies we track by market value.

Shareholding pattern

As of Mar 2026, promoters held 48.80%, foreign institutional investors (FIIs) 16.33%, domestic institutional investors (DIIs) 21.38%, the government 0.00%, public shareholders 13.48% of JB Chemicals & Pharmaceuticals Limited.

Promoter holding rose from 47.55% to 48.80% over the latest period.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹38,677 Cr
Current Price ?
₹2,408.9
P/E ?
54.54above ind
Industry P/E ?
35.00
P/B ?
9.30
P/S ?
9.33
P/FCF ?
62.08
Enterprise Value ?
₹38,681 Cr
EV/EBITDA ?
34.93
PEG ?
2.60
Earnings Yield ?
2.4%
Dividend Yield ?
0.91%
Profitability & Returns
Sales (TTM) ?
₹4,148 Cr
OPM ?
26.7%
Profit after tax (TTM) ?
₹709 Cr
EPS (TTM) ?
₹44.16
ROCE ?
25.0%
ROE ?
17.0%
ROA ?
14.3%
Growth
Sales — latest qtr ?
₹904 Cr
PAT — latest qtr ?
₹101 Cr
YoY qtr sales growth ?
-4.8%
YoY qtr profit growth ?
-30.7%
Sales growth (3y) ?
10%
Sales growth (5y) ?
15%
Profit growth (3y) ?
21%
Profit growth (5y) ?
12%
Financial Health
Debt ?
₹4 Cr
Debt to Equity ?
0.00
Interest Coverage ?
173.2
Current Ratio ?
N/A
Ownership
Promoter holding ?
48.80%
Change in promoter holding ?
1.07%
Pledged percentage ?
N/A
Market
Return 3 months ?
20.1%
Return 6 months ?
30.5%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Mar bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026 YoY % QoQ %
Sales 7937628968828458621,0041,0019639491,0941,0851,065904 -4.8% -15.1%
Operating Profit 175164232244223198280271255226301310296201 -11.2% -32.1%
Other Income 3568717610814151518-15 -203.6% -182.1%
Interest 814121012962311121 -31.0% -46.8%
Depreciation 2832313234414142424643444550 +7.7% +10.3%
Profit Before Tax 141122194209184165240237218193272279267135 -30.1% -49.4%
Net Profit 10688142151134126177175162146202208198101 -30.7% -49.0%
EPS 13.7211.3318.399.728.628.2211.3911.2410.469.3612.9913.2912.636.31 -32.6% -50.0%
OPM % 22.0% 21.5% 25.9% 27.6% 26.4% 23.0% 27.9% 27.0% 26.4% 23.8% 27.5% 28.5% 27.8% 22.2% -6.7% -20.1%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹3,918 Cr ₹4,148 Cr ₹4,148 Cr +5.9%
Operating Profit ₹1,032 Cr ₹1,107 Cr ₹1,107 Cr +7.3%
OPM % 26.34% 26.70% 26.70% +1.4%
NPM % 16.83% 17.10% 17.10% +1.6%
Other Income ₹38 Cr ₹33 Cr ₹33 Cr -13.4%
Depreciation ₹171 Cr ₹182 Cr ₹182 Cr +6.7%
Interest ₹12 Cr ₹5 Cr ₹5 Cr -54.5%
EBIT ₹861 Cr ₹925 Cr ₹925 Cr +7.4%
PBT ₹887 Cr ₹953 Cr ₹953 Cr +7.4%
Tax ₹228 Cr ₹210 Cr ₹210 Cr -8.0%
Net Profit ₹660 Cr ₹709 Cr ₹709 Cr +7.5%
EPS ₹42.45 ₹45.22 ₹45.22 +6.5%
Material Cost ₹1,317 Cr ₹1,054 Cr ₹1,054 Cr -20.0%
Employee Cost ₹688 Cr ₹574 Cr ₹574 Cr -16.5%
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 15161616 +0.0%
Reserves 2,4652,9083,4184,143 +21.2%
Borrowings 572378284 -85.7%
Other Liabilities 495687804799 -0.6%
Total Liabilities 3,5473,9884,2654,962 +16.3%
Fixed Assets 1,9012,0041,9681,885 -4.2%
CWIP 55766374 +17.5%
Investments 206388345765 +121.7%
Other Assets 1,3851,5191,8892,237 +18.4%
Total Assets 3,5473,9884,2654,962 +16.3%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 626801902704 -22.0%
Cash from Investing Activity -962-404-296-586 -98.0%
Cash from Financing Activity 357-385-580-123 +78.8%
Net Cash Flow 201127-5 -118.5%
Free Cash Flow -138540783623 -20.4%
CFO/OP 104%104%107%87% -18.7%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 67727669 -9.2%
Inventory Days 134155147192 +30.6%
Days Payable 75110114110 -3.5%
Cash Conversion Cycle 127117109151 +38.5%
Working Capital Days 815579126 +59.5%
ROCE % 22%25%26%25% -3.8%

👥 Shareholding (latest 4 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026 % Chg
Promoters 47.73%47.56%47.55%48.80% +2.6%
FIIs 17.77%15.31%14.88%16.33% +9.7%
DIIs 19.62%22.83%23.35%21.38% -8.4%
Government 0.00%0.00%0.00%0.00% —
Public 14.87%14.31%14.21%13.48% -5.1%
No. of Shareholders 70,06471,95769,33874,043 +6.8%

⚖️ Peer comparison

Industry: Drug Manufacturers - Specialty & Generic · top 25 of 31 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SUNPHARMA Sun Pharmaceutical ₹1,840.00 441,478 36.5 59,911 12,104 29.8% 20.2% 11.2% 5.1% 10.5% 27.0%
2 DIVISLAB Divi's Laboratories ₹9,235.00 245,160 83.8 11,230 2,925 35.3% 26.0% 12.8% 16.7% 27.8% 65.5%
3 TORNTPHARM Torrent Pharmaceuticals ₹4,931.00 187,559 87.1 15,723 2,156 33.0% 13.7% 21.4% 11.9% 54.8% 3.3%
4 ZYDUSLIFE Zydus Lifesciences ₹1,162.20 115,930 23.2 27,148 5,070 31.2% 18.7% 16.8% 12.0% 16.2% 14.5%
5 CIPLA Cipla ₹1,366.00 110,353 32.7 28,324 3,356 18.7% 11.8% 2.2% -26.7% 2.3% -39.2%
6 LAURUSLABS Laurus Labs ₹1,969.00 106,387 97.2 7,270 1,090 28.0% 15.0% 22.7% 147.9% 29.1% 123.9%
7 DRREDDY Dr. Reddy's ₹1,165.50 97,085 29.3 28,704 3,273 15.3% 11.4% -10.4% -25.8% -5.6% -69.2%
8 AUROPHARMA Aurobindo Pharma ₹1,679.80 96,652 26.2 34,935 3,711 20.3% 10.6% 6.1% 0.6% 16.3% 25.2%
9 LUPIN Lupin ₹2,095.00 95,797 17.9 27,958 5,356 31.5% 19.2% 23.1% 62.0% 31.9% 87.8%
10 MANKIND Mankind Pharma ₹2,280.00 94,174 46.1 14,738 2,067 26.0% 14.0% 16.3% -3.7% 12.9% 29.1%
11 GLENMARK Glenmark Pharmaceuticals ₹2,419.20 68,276 38.0 17,737 1,797 27.0% 10.1% -61.2% -67.4% 23.1% 927.9%
12 ALKEM Alkem Laboratories ₹5,243.50 62,694 29.1 15,081 2,187 20.1% 14.5% 13.5% 7.6% 10.9% -21.6%
13 ABBOTINDIA Abbott India ₹25,860.00 54,951 34.0 7,005 1,615 28.1% 23.1% 8.1% 9.7% 4.4% 17.2%
14 IPCALAB Ipca Laboratories ₹1,964.20 49,833 38.0 10,125 1,379 22.0% 13.6% 7.9% 55.0% 20.8% 82.2%
15 GLAND Gland Pharma ₹2,935.90 48,433 47.1 6,431 1,028 25.3% 16.0% -64.7% -48.4% 22.3% 96.7%
16 AJANTPHARM Ajanta Pharma ₹3,398.90 42,472 37.4 5,777 1,135 25.4% 19.7% 17.3% 14.8% 24.8% 30.9%
17 JBCHEPHARM J. B. ₹2,416.10 38,793 53.4 4,148 709 26.7% 17.1% 5.9% 7.5% -4.8% -30.7%
18 EMCURE EMCURE PHARMACEUTICALS ₹1,975.10 37,470 37.0 9,684 1,019 20.4% 10.5% 16.6% 33.1% 22.8% 36.0%
19 WOCKPHARMA Wockhardt ₹2,021.50 32,848 92.5 3,133 353 19.9% 11.3% -2.3% 342.1% 25.9% 199.1%
20 NEULANDLAB Neuland Laboratories ₹23,455.00 30,093 82.7 2,023 365 28.4% 18.0% 37.0% 40.2% 136.3% 666.0%
21 PPLPHARMA Piramal Pharma ₹211.50 28,024 113.5 9,206 247 11.0% 2.7% -3.1% -37.9% 17.4% -161.3%
22 GRANULES Granules India ₹885.60 21,945 32.8 5,633 663 22.7% 11.8% 19.7% 18.8% 22.0% 59.3%
23 CAPLIPOINT Caplin Point ₹2,752.60 20,923 31.4 2,287 678 34.8% 29.7% 12.9% 20.2% 19.6% 18.8%
24 ERIS Eris Lifesciences ₹1,358.00 18,820 29.0 3,230 666 35.2% 20.6% 8.2% 72.6% 13.0% 14.6%
25 ASTRAZEN AstraZeneca Pharma ₹6,755.00 16,888 99.6 2,432 170 9.4% 7.0% 32.7% 62.1% 29.7% -32.1%
❓ Frequently asked questions
What was JB Chemicals & Pharmaceuticals Limited's revenue in Q4 FY26?
JB Chemicals & Pharmaceuticals Limited reported revenue of ₹904 crore for the quarter ended March 2026 (Q4 FY26), down 4.8% from ₹949 crore in the same quarter last year, and down 15.1% sequentially over the December 2025 quarter.
What was JB Chemicals & Pharmaceuticals Limited's net profit in Q4 FY26?
Net profit fell 30.7% year-on-year to ₹101 crore, from ₹146 crore. Earnings per share (EPS) came in at ₹6.31.
What is JBCHEPHARM's market capitalisation and P/E ratio?
At the current price of ₹2,408.90, JBCHEPHARM has a market capitalisation of ₹38,677 crore and a trailing P/E of about 54.5.
Who owns JB Chemicals & Pharmaceuticals Limited? (shareholding pattern)
As of Mar 2026, promoters held 48.80%, foreign institutional investors (FIIs) 16.33%, domestic institutional investors (DIIs) 21.38%, the government 0.00%, public shareholders 13.48% of JB Chemicals & Pharmaceuticals Limited.
TTM ends 2026-03-31. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI